Related Experiment Videos
Remoxipride: pharmacokinetics and effect on plasma prolactin
G Movin-Osswald1, M Hammarlund-Udenaes
1Department of Clinical Pharmacology, Astra Research Centre AB, Södertlje, Sweden.
British Journal of Clinical Pharmacology
|September 1, 1991
Summary
This study examined remoxipride pharmacokinetics in healthy subjects. Remoxipride demonstrated high bioavailability across different formulations, with similar prolactin level changes.
Area of Science:
- Pharmacology
- Neuroscience
Background:
- Remoxipride is a novel neuroleptic agent.
- Understanding its pharmacokinetic profile is crucial for therapeutic application.
Purpose of the Study:
- To investigate the pharmacokinetics of remoxipride in healthy subjects.
- To assess the impact of different remoxipride formulations on plasma prolactin concentrations.
Main Methods:
- Cross-over study involving 15 healthy subjects.
- Administration of intravenous, intramuscular, and oral (immediate release capsules) remoxipride formulations.
- Measurement of plasma prolactin concentrations.
Main Results:
- Absolute bioavailability for intramuscular and oral routes exceeded 90%, suggesting minimal first-pass metabolism.
- Mean elimination half-life was 4.8 ± 1.4 hours.
- Plasma prolactin increases were consistent across all tested remoxipride formulations and doses.
Conclusions:
- Remoxipride exhibits favorable pharmacokinetic properties with high bioavailability.
- The neuroleptic's effect on prolactin is formulation-independent at the tested doses.